What it is
HGH Fragment 176-191 is the C-terminal fragment of human growth hormone (amino acids 176–191) studied for its lipolytic signaling activity — the portion of the HGH molecule associated with fat-mobilization effects. AOD-9604 is the modified/research-stable derivative of this same 176–191 sequence; the two are frequently discussed together in metabolic research.
Evidence boundary
Preclinical and metabolic research context. Research use is limited to laboratory and education contexts.
Trial evidence
- Studies on the 176–191 fragment focus on adipocyte lipolysis signaling; AOD-9604 (its stabilized derivative) has the larger human-facing research history.
Preparation and measurement
Reconstitution: 5 mg vial + 2 mL BAC = 2.5 mg/mL (1 U = 25 mcg).
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Conservative start | 250 mcg | 10 U (0.1 mL) | 1× daily | 1.75 mg/week |
| Standard research | 500 mcg | 20 U (0.2 mL) | 1–2× daily | 3.5–7 mg/week |
Conservative start
- Dose
- 250 mcg
- Draw / measure
- 10 U (0.1 mL)
- Frequency
- 1× daily
- Weekly total
- 1.75 mg/week
Standard research
- Dose
- 500 mcg
- Draw / measure
- 20 U (0.2 mL)
- Frequency
- 1–2× daily
- Weekly total
- 3.5–7 mg/week
Weekly totals apply only during the active phase.
Titration rules
- Common range: 250–500 mcg per injection, 1–2 times daily.
- Typical cycle: 4–8 weeks with a 2–4 week break.
- Often run alongside a GH pulse or metabolic peptide; check mixability before co-injecting.
- Fragment 176-191 and AOD-9604 overlap heavily — pick one, don’t double-stack them without reason.